{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T15:59:43Z","timestamp":1704729583918},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00393-021-01117-w","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T12:02:36Z","timestamp":1636027356000},"page":"22-27","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Morbus Still\u00a0\u2013 \u00c4hnlichkeiten und Differenzen zwischen juveniler und adulter Form"],"prefix":"10.1007","volume":"81","author":[{"given":"Andrea","family":"Regel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"F\u00f6ll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin A.","family":"Kriegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"1117_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1177\/095952879708000106","volume":"80","author":"GF Still","year":"1897","unstructured":"Still\u00a0GF (1897) On a\u00a0form of chronic joint disease in children. Med Chir Trans 80:47\u201360.9","journal-title":"Med Chir Trans"},{"key":"1117_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/ard.45.1.1","volume":"45","author":"EB Hamilton","year":"1986","unstructured":"Hamilton\u00a0EB (1986) George Frederic Still. Ann Rheum Dis 45:1\u20135","journal-title":"Ann Rheum Dis"},{"key":"1117_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1136\/ard.30.2.121","volume":"30","author":"EG Bywaters","year":"1971","unstructured":"Bywaters\u00a0EG (1971) Still\u2019s disease in the adult. Ann Rheum Dis 30:121\u2013133","journal-title":"Ann Rheum Dis"},{"key":"1117_CR4","first-page":"150","volume":"45","author":"JR Silva","year":"2020","unstructured":"Silva\u00a0JR, Brito\u00a0I (2020) Systemic juvenile idiopathic arthritis versus adult-onset Still s disease: the pertinence of changing the current classification criteria. Acta Reumatol Port 45:150\u2013151","journal-title":"Acta Reumatol Port"},{"key":"1117_CR5","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty\u00a0RE, Southwood\u00a0TR, Manners\u00a0P et\u00a0al (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J\u00a0Rheumatol 31:390\u2013392","journal-title":"J Rheumatol"},{"key":"1117_CR6","first-page":"424","volume":"19","author":"M Yamaguchi","year":"1992","unstructured":"Yamaguchi\u00a0M, Ohta\u00a0A, Tsunematsu\u00a0T et\u00a0al (1992) Preliminary criteria for classification of adult Still\u2019s disease. J\u00a0Rheumatol 19:424\u2013430","journal-title":"J Rheumatol"},{"key":"1117_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12969-018-0224-2","volume":"16","author":"CH Hinze","year":"2018","unstructured":"Hinze\u00a0CH, Holzinger\u00a0D, Lainka\u00a0E et al (2018) Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online\u00a0J 16:7","journal-title":"Pediatr Rheumatol Online J"},{"key":"1117_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41584-021-00590-6","volume":"17","author":"PA Nigrovic","year":"2021","unstructured":"Nigrovic\u00a0PA, Colbert\u00a0RA, Holers\u00a0VM et\u00a0al (2021) Biological classification of childhood arthritis: roadmap to a\u00a0molecular nomenclature. Nat Rev Rheumatol 17:257\u2013269","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"1117_CR9","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3390\/jcm10040733","volume":"10","author":"S Tomaras","year":"2021","unstructured":"Tomaras\u00a0S, Goetzke\u00a0CC, Kallinich\u00a0T et al (2021) Adult-onset still\u2019s disease: clinical aspects and therapeutic approach. J\u00a0Clin Med 10(4):733. https:\/\/doi.org\/10.3390\/jcm10040733","journal-title":"J Clin Med"},{"key":"1117_CR10","first-page":"S168","volume":"28","author":"B Manger","year":"2010","unstructured":"Manger\u00a0B, Rech\u00a0J, Schett\u00a0G (2010) Use of methotrexate in adult-onset Still\u2019s disease. Clin Exp Rheumatol 28:S168\u2013171","journal-title":"Clin Exp Rheumatol"},{"key":"1117_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","volume":"14","author":"E Feist","year":"2018","unstructured":"Feist\u00a0E, Mitrovic\u00a0S, Fautrel\u00a0B (2018) Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease. Nat Rev Rheumatol 14:603\u2013618","journal-title":"Nat Rev Rheumatol"},{"key":"1117_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaut.2018.07.018","volume":"93","author":"R Giacomelli","year":"2018","unstructured":"Giacomelli\u00a0R, Ruscitti\u00a0P, Shoenfeld\u00a0Y (2018) A comprehensive review on adult onset Still\u2019s disease. J\u00a0Autoimmun 93:24\u201336","journal-title":"J Autoimmun"},{"key":"1117_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/art.41107","volume":"72","author":"C Kessel","year":"2020","unstructured":"Kessel\u00a0C, Hedrich\u00a0CM, Foell\u00a0D (2020) Innately adaptive or truly autoimmune: is there something unique about systemic juvenile idiopathic arthritis? Arthritis Rheumatol 72:210\u2013219","journal-title":"Arthritis Rheumatol"},{"key":"1117_CR14","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/art.40099","volume":"69","author":"C Kessel","year":"2017","unstructured":"Kessel\u00a0C, Lippitz\u00a0K, Weinhage\u00a0T et al (2017) Proinflammatory cytokine environments can drive Interleukin-17 overexpression by gamma\/delta T cells in systemic juvenile idiopathic arthritis. Arthritis Rheumatol 69:1480\u20131494","journal-title":"Arthritis Rheumatol"},{"key":"1117_CR15","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1136\/annrheumdis-2019-215051","volume":"78","author":"F Gohar","year":"2019","unstructured":"Gohar\u00a0F, Mcardle\u00a0A, Jones\u00a0M et\u00a0al (2019) Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis. Ann Rheum Dis 78:1107\u20131113","journal-title":"Ann Rheum Dis"},{"key":"1117_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-med-061813-012806","volume":"66","author":"GS Schulert","year":"2015","unstructured":"Schulert\u00a0GS, Grom\u00a0AA (2015) Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies. Annu Rev Med 66:145\u2013159","journal-title":"Annu Rev Med"},{"key":"1117_CR17","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1182\/blood-2011-07-370148","volume":"118","author":"K Zhang","year":"2011","unstructured":"Zhang\u00a0K, Jordan\u00a0MB, Marsh\u00a0RA et al (2011) Hypomorphic mutations in PRF1, MUNC13\u20114, and STXBP2 are associated with adult-onset familial HLH. Blood 118:5794\u20135798","journal-title":"Blood"},{"key":"1117_CR18","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1002\/art.38793","volume":"66","author":"KM Kaufman","year":"2014","unstructured":"Kaufman\u00a0KM, Linghu\u00a0B, Szustakowski\u00a0JD et al (2014) Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 66:3486\u20133495","journal-title":"Arthritis Rheumatol"},{"key":"1117_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00115-6","author":"C Kessel","year":"2021","unstructured":"Kessel\u00a0C, Fall\u00a0N, Grom\u00a0A et\u00a0al (2021) Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study. Lancet Rheumatol. https:\/\/doi.org\/10.1016\/S2665-9913(21)00115-6","journal-title":"Lancet Rheumatol"},{"key":"1117_CR20","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/ng.3089","volume":"46","author":"SW Canna","year":"2014","unstructured":"Canna\u00a0SW, de Jesus\u00a0AA, Gouni\u00a0S et\u00a0al (2014) An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 46:1140\u20131146","journal-title":"Nat Genet"},{"key":"1117_CR21","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/ng.3066","volume":"46","author":"N Romberg","year":"2014","unstructured":"Romberg\u00a0N, Al Moussawi\u00a0K, Nelson-Williams\u00a0C et al (2014) Mutation of NLRC4 causes a\u00a0syndrome of enterocolitis and autoinflammation. Nat Genet 46:1135\u20131139","journal-title":"Nat Genet"},{"key":"1117_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41579-020-0367-2","volume":"18","author":"WE Ruff","year":"2020","unstructured":"Ruff\u00a0WE, Greiling\u00a0TM, Kriegel\u00a0MA (2020) Host-microbiota interactions in immune-mediated diseases. Nat Rev Microbiol 18:521\u2013538","journal-title":"Nat Rev Microbiol"},{"key":"1117_CR23","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/annrheumdis-2011-200598","volume":"71","author":"D Holzinger","year":"2012","unstructured":"Holzinger\u00a0D, Frosch\u00a0M, Kastrup\u00a0A et al (2012) The Toll-like receptor 4 agonist MRP8\/14 protein complex is a\u00a0sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 71:974\u2013980","journal-title":"Ann Rheum Dis"},{"key":"1117_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13075-016-1069-z","volume":"18","author":"F Gohar","year":"2016","unstructured":"Gohar\u00a0F, Kessel\u00a0C, Lavric\u00a0M et\u00a0al (2016) Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks? Arthritis Res Ther 18:163","journal-title":"Arthritis Res Ther"},{"key":"1117_CR25","doi-asserted-by":"publisher","first-page":"e0235326","DOI":"10.1371\/journal.pone.0235326","volume":"15","author":"P Di Benedetto","year":"2020","unstructured":"Di Benedetto\u00a0P, Cipriani\u00a0P, Iacono\u00a0D et al (2020) Ferritin and C\u2011reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset still\u2019s disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. PLoS ONE 15:e235326","journal-title":"PLoS ONE"},{"issue":"121","key":"1117_CR26","first-page":"52","volume":"37","author":"QY Hu","year":"2019","unstructured":"Hu\u00a0QY, Zeng\u00a0T, Sun\u00a0CY et al (2019) Clinical features and current treatments of adult-onset Still\u2019s disease: a\u00a0multicentre survey of 517\u00a0patients in China. Clin Exp Rheumatol 37(121):52\u201357","journal-title":"Clin Exp Rheumatol"},{"key":"1117_CR27","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s10067-016-3308-8","volume":"35","author":"P Sfriso","year":"2016","unstructured":"Sfriso\u00a0P, Priori\u00a0R, Valesini\u00a0G et al (2016) Adult-onset Still\u2019s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245\u00a0patients. Clin Rheumatol 35:1683\u20131689","journal-title":"Clin Rheumatol"},{"key":"1117_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MD.0000000000000021","volume":"93","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin\u00a0M, Maucort-Boulch\u00a0D, Hot\u00a0A et al (2014) Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57\u00a0patients. Medicine 93:91\u201399","journal-title":"Medicine"},{"key":"1117_CR29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/00005792-200205000-00003","volume":"81","author":"B Fautrel","year":"2002","unstructured":"Fautrel\u00a0B, Zing\u00a0E, Golmard\u00a0JL et al (2002) Proposal for a\u00a0new set of classification criteria for adult-onset still disease. Medicine 81:194\u2013200","journal-title":"Medicine"},{"key":"1117_CR30","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jfma.2011.06.013","volume":"111","author":"HY Tsai","year":"2012","unstructured":"Tsai\u00a0HY, Lee\u00a0JH, Yu\u00a0HH et al (2012) Initial manifestations and clinical course of systemic onset juvenile idiopathic arthritis: a\u00a0ten-year retrospective study. J\u00a0Formos Med Assoc 111:542\u2013549","journal-title":"J Formos Med Assoc"},{"key":"1117_CR31","first-page":"343","volume":"35","author":"EM Behrens","year":"2008","unstructured":"Behrens\u00a0EM, Beukelman\u00a0T, Gallo\u00a0L et\u00a0al (2008) Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania systemic onset juvenile arthritis registry (PASOJAR). J\u00a0Rheumatol 35:343\u2013348","journal-title":"J Rheumatol"},{"key":"1117_CR32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/pr.2013.187","volume":"75","author":"CK Correll","year":"2014","unstructured":"Correll\u00a0CK, Binstadt\u00a0BA (2014) Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis. Pediatr Res 75:176\u2013183","journal-title":"Pediatr Res"},{"key":"1117_CR33","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/art.38615","volume":"66","author":"PA Nigrovic","year":"2014","unstructured":"Nigrovic\u00a0PA (2014) Review: is there a\u00a0window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol 66:1405\u20131413","journal-title":"Arthritis Rheumatol"},{"key":"1117_CR34","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/art.40865","volume":"71","author":"NM Ter Haar","year":"2019","unstructured":"Ter Haar\u00a0NM, van Dijkhuizen\u00a0EHP, Swart\u00a0JF et al (2019) Treatment to target using recombinant Interleukin\u20111 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a\u00a0five-year follow-up study. Arthritis Rheumatol 71:1163\u20131173","journal-title":"Arthritis Rheumatol"},{"key":"1117_CR35","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","volume":"66","author":"SJ Vastert","year":"2014","unstructured":"Vastert\u00a0SJ, de Jager\u00a0W, Noordman\u00a0BJ et al (2014) Effectiveness of first-line treatment with recombinant interleukin\u20111 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a\u00a0prospective cohort study. Arthritis Rheumatol 66:1034\u20131043","journal-title":"Arthritis Rheumatol"},{"key":"1117_CR36","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic\u00a0PA, Mannion\u00a0M, Prince\u00a0FH et al (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63:545\u2013555","journal-title":"Arthritis Rheum"},{"key":"1117_CR37","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto\u00a0N, Brunner\u00a0HI, Quartier\u00a0P et\u00a0al (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N\u00a0Engl J Med 367:2396\u20132406","journal-title":"N Engl J Med"},{"key":"1117_CR38","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/annrheumdis-2020-217155","volume":"79","author":"C Kedor","year":"2020","unstructured":"Kedor\u00a0C, Listing\u00a0J, Zernicke\u00a0J et al (2020) Canakinumab for treatment of adult-onset Still\u2019s disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis 79:1090\u20131097","journal-title":"Ann Rheum Dis"},{"key":"1117_CR39","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti\u00a0F, Brunner\u00a0HI, Ruperto\u00a0N et\u00a0al (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N\u00a0Engl J Med 367:2385\u20132395","journal-title":"N Engl J Med"},{"key":"1117_CR40","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/art.38398","volume":"66","author":"F Ortiz-Sanjuan","year":"2014","unstructured":"Ortiz-Sanjuan\u00a0F, Blanco\u00a0R, Calvo-Rio\u00a0V et al (2014) Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still\u2019s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol 66:1659\u20131665","journal-title":"Arthritis Rheumatol"},{"key":"1117_CR41","first-page":"840","volume":"77","author":"C Gabay","year":"2018","unstructured":"Gabay\u00a0C, Fautrel\u00a0B, Rech\u00a0J et al (2018) Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease. Ann Rheum Dis 77:840\u2013847","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-01117-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-021-01117-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-01117-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T16:46:49Z","timestamp":1643993209000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-021-01117-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1117"],"URL":"https:\/\/doi.org\/10.1007\/s00393-021-01117-w","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]},"assertion":[{"value":"22 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Regel gibt  an, dass kein Interessenkonflikt besteht. M.\u00a0Kriegel gibt die folgenden potenziellen Interessenskonflikte an: Beratert\u00e4tigkeiten f\u00fcr die Firmen Novartis, Glaxo-Smith Kline, Bristol-Meyers Squibb, Merck Sharp & Dohme, Eligo Biosciences, und vorige Forschungsunterst\u00fctzung von AbbVie und Anstellung bei Roche. D. F\u00f6ll gibt die folgenden potenziellen Interessenskonflikte an: Beratert\u00e4tigkeiten f\u00fcr die Firmen Novartis, Sobi und Boehringer. Forschungsunterst\u00fctzung durch die Firmen Novartis, Sobi und Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}